MedTech Acquisition Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 22.4%
$MTAC
Medical Specialities
Health Care
MedTech Acquisition Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 22.4%
Save time and jump to the most important pieces.
Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors,
TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu
MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li
New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)